Biotech Daily

Wednesday July 22, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: PROTEOMICS UP 23%; SALUDA DOWN 18%**

*** CONNNEQT RECEIPTS UP 65% TO $6m**

*** TETRATHERIX $4.2m RECEIPTS FROM SUPERPOWER LICENCE**

*** CAMBIUM 'COMMITMENT' FOR $1m PLACEMENT**

*** RADIOPHARM: 'RAD101 MRI CONCORDANCE, RAD204 PARTIAL RESPONSE', HALT**

*** OPTISCAN, INVUE, INFORM MAYO BREAST SURGERY STUDY**

*** MONASH UNI OPENS $2.9m ROBOTIC DRUG RESEARCH LAB**

*** ADELAIDE UNI FINDS BLOOD CANCER BIO-MARKER**

*** PROTEOMICS APPOINTS HEALIUS AUSTRALIA PROMARKER DISTRIBUTOR**

*** BLS, TREXAPHARM PARTNER FOR TREXAVIVE IN DEPRESSION**

*** PYC OK TO CONTINUE PHASE Ib PYC-003 KIDNEY DISEASE TRIAL**

*** PARADIGM RECEIVES $5.75m FEDERAL R&D TAX INCENTIVE**

*** PAINCHEK RECEIVES $1.1m FEDERAL R&D TAX INCENTIVE**

*** MEMPHASYS 2m CHAIR OPTIONS, 8m ADVISOR SHARES EGM**

*** VITURA APPOINTS JAMES FRAYNE CFO, TRUDY ADAMS HEAD OF STRATEGY**

MARKET REPORT

The Australian stock market was up 0.34 percent on Wednesday July 22, 2026, with the ASX200 up 29.7 points to 8,823.0 points. Thirteen of the Biotech Daily Top 40 companies were up, 22 fell and five traded unchanged. All four Big Caps fell.

Proteomics was the best (see below), up 3.5 cents or 23.3 percent to 18.5 cents, with 2.2 million shares traded. Optiscan climbed 10.7 percent; Dimerix was up 8.7 percent; Paradigm improved 6.1 percent; Clarity and Resonance were up more than four percent; Neuren was up 3.2 percent; Artrya and Immutep rose two percent or more; with Aroa, Mesoblast, Orthocell and Racura up by less than one percent.

Saluda led the falls, down 9.5 cents or 18.1 percent to 43 cents, with 878,285 shares traded. Atomo lost 10.5 percent; Compumedics was down 6.1 percent; Lumos lost 5.05 percent; Botanix, Cochlear, EBR, Prescient and Syntara fell more than four percent; Amplia, Medical Developments, Micro-X and Pro Medicus were down more than three percent; Alcidion, Avita, CSL and Telix shed more than two percent; Clinuvel, Cyclopharm, Imricor and Imugene were down more than one percent; with 4D Medical, Emvision, Nanosonics, Resmed and Starpharma down by less than one percent.

CONNEQT HEALTH

Conneqt says customer receipts for the year to June 30, 2026 were up 65.0 percent to $5,656,000, compared to the previous corresponding period.
Conneqt said receipts for the three months to June 30, 2026 from sales of its Pulse blood pressure monitor were up 75.1 percent to $1,884,000, compared to the prior corresponding period.
The company said it had a three-month cash burn of $2,466,000, with cash and cash equivalents of $2,566,000 at June 30, 2026 compared to $2,433,000 at June 30, 2025, leaving it with one quarter of cash.
Conneqt said subscription revenue was increasing daily, with a strong sales pipeline in the US and Australia, $850,000 expected in research and clinical trial trade receivables, $825,000 in a placement as well as $500,000 in a share purchase plan.
Last month, the company said it had “commitments” to raise $5,500,000 at 2.2 cents a share in a placement, with a $500,000 share purchase plan to follow and further details including a timetable to be announced separately (BD: Jun 19, 2026).
Today, Conneqt said it had a $1,115,000 Federal Research and Development Incentive loan with Sydney’s Kashcade RD1 at 1.38 percent monthly interest, repayable by November 30, 2026.
Conneqt was up 0.1 cents or five percent to 2.1 cents.

TETRATHERIX

Tetratherix says receipts from customers for the year to June 30,2026 was $4,201,000 following a $4.2 million licence fee from the Los Angeles-based Superpower Health.
Earlier this year, Tetratherix said it had a 10-year, $US3 million a year deal to licence its Tetramatrix “platform polymer” to Superpower Health Inc (BD: Mar 16, 2026).
At the time, the company said Superpower would research and develop its synthetic thermo-responsive enabling polymer platform, or Stepp, Tetramatrix platform polymer for the “nasal delivery of longevity and metabolic compounds such as [glucagon-like peptide-1] GLP-1”, including Ozempic and Wegovy, peptides and hormones.
Previously, Tetratherix said Tetramatrix was “the world’s first bio-stealth fluid matrix and is being used to develop clinical products applicable across numerous areas including bone regeneration, tissue spacing and tissue healing” (BD: Jun 6, 2025).
Today, the company said it had a positive cash flow of $1,172,000 for the three months, with cash and cash equivalents of $34,364,000 at June 30, 2026 compared to $29,336,000 at June 30, 2025.
Tetratherix fell 10 cents or 1.5 percent to $6.65.

CAMBIUM BIO

Cambium says it has “a firm commitment” to raise $1,008,000 at 48 cents a share in a placement to existing shareholder Chun Yi (Brandon) Wu.
Cambium said the issue price was a 17.1 percent premium to the last closing price and that following the placement Mr Wu’s shareholding would increase from 12.25 percent to about 18.5 percent of the company.
The company said the placement formed “part of a broader … strategy” to finance its 475-patient, phase III trial of Elate Ocular for moderate to severe dry eye disease.
Cambium said the placement shares would be issued under its existing 10 percent placement capacity within five days and were not subject to shareholder approval.
Cambium was up two cents or 4.9 percent to 43 cents.

RADIOPHARM THERANOSTICS

Radiopharm says its phase IIb trial shows RAD101 has 93 percent concordance with MRI for imaging brain tumors, and it has a partial response in its phase I RAD204 trial.
Earlier this year, Radiopharm said it had dosed all 30 patients in its US, phase IIb trial of Fluorine-18 radio-labelled RAD101 for imaging confirmed recurrent brain metastases from solid tumors (BD: Apr 16, 2026).
Today, the company said that the phase IIb trial 93 percent concordance with magnetic resonance imaging (MRI) for brain metastases after radio-therapy in 14 patients "showed substantial and selective tumor uptake of RAD101", with images confirming metabolic activity in positron emission tomography (PET) compared to equivocal MRI findings.
Radiopharm said 14 patients with evaluable six-month follow-up showed "preliminary 86 percent sensitivity, representing a strong positive trend"; with sensitivity measuring an imaging test's ability to correctly identify patients with disease.
The company said the phase I trial showed a partial response at the highest dose level of 90 millicuries, with the patient remaining progression free beyond seven months.
In 2024, Radiopharm said it dosed the first of 21 patients in the phase I, dose-escalation, study of RAD204 for lung cancer, and last year said it had approval to begin dosing the third cohort with 90 millicuries of lutetium-177 RAD204 (BD: Jul 10, 2024; Nov 12, 2025).
Today, the company said initial data from all phase I cohorts showed tumor uptake in the PD-L1-positive lesions "in line with published results from the previously completed imaging study"; with a second patient remaining progression-free on treatment with RAD204, with early tumor shrinkage observed after first treatment.
Radiopharm said RAD204 was "generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far".
Separately, the company requested a trading halt "pending an announcement by the company in relation to a material capital raising".
Trading will resume on July 24, 2026, or on an earlier announcement.
Radiopharm last traded at 1.9 cents.

OPTISCAN IMAGING

Optiscan says with the Mayo Clinic it will conduct a 35-patient, US study of its Invue in-vivo and Inform ex-vivo microscopes for imaging during breast conserving surgery.
Optiscan said recruitment was open, with the study to assess intra-operative breast cancer margin assessment after lumpectomy using its Invue and Inform devices.
The company said the study could generate evidence for planned US Food and Drug Administration 510(k) submissions for both devices by 2027 and support artificial intelligence (A.I.) and machine learning for breast cancer tissue assessment.
Optiscan managing-director Prof Camile Farah said the agreement allowed it to begin "a US clinical study designed to support our planned 510(k) premarket submissions and potentially validate the role of Invue and Inform in breast cancer surgery".
"Patient recruitment in the US is a major milestone in generating high-quality clinical evidence and refining our technologies for demanding surgical and pathology workflows," Prof Farah said.
"By evaluating both devices within one clinical workflow, we are building evidence for a potentially integrated surgical-pathology solution that could support faster intra-operative decisions and extend point-of-care tissue assessment into digital pathology," Prof Farah said. "Breast cancer surgery is an important first commercial application given the scale of the market and the clinical need for better intra-operative margin assessment."
Optiscan was up 1.5 cents or 10.7 percent to 15.5 cents.

MONASH UNIVERSITY

Monash University says it will open a $2.9 million robotic laboratory for inventing, conducting trials and commercializing medicines by Australian researchers.
Monash University said the facility would be accessible nationally and was backed by a Medical Research Future Fund National Critical Research Infrastructure grant.
The University said the facility would include “Australia’s first automated system for high-throughput x-ray crystallography, often referred to as HTX, at the Australian Synchrotron”.
Monash University said an HTX was “a powerful scientific technique that involves blasting tiny biological crystals with x-rays to map the exact 3-dimensional shape of disease-causing proteins, revealing how a molecule binds to its target”.
The University said the facility would “boost sovereign capability in therapeutics, supporting hundreds of researchers across the country investigating treatments for over 40 disease targets, including cancer, HIV, bacterial infections, and neuro-degeneration”; and the facility filled “a critical gap in Australia’s drug development pipeline, giving commercial partners the confidence” to invest in local biotechnology.
The University said the five-year project was a “large collaborative effort”.
Monash Institute of Pharmaceutical Sciences head of medicinal chemistry Prof Martin Scanlon said the technology would provide “incalculable ability to boost capability and capacity while saving time and accelerating productivity”.
“When we’re creating a new medicine, we need to design a compound to fit into a specific pocket of a protein, but the protein often changes shape in response,” Prof Scanlon said.
“HTX will attract investment and importantly grow the Australian biotechnology and clinical trials economy as more partners invest locally to bring new clinical candidates to market,” Prof Scanlon said. “Analysis of drug discovery projects successful in generating a clinical candidate showed 65 percent relied on structural information, most of which were derived from x-ray crystallography.”

ADELAIDE UNIVERSITY

Adelaide University says a retrospective in-vitro study has found a bio-marker for the detection of multiple myeloma, allowing more personalized and effective treatments.
Adelaide University said that high levels of the desmoglein-2 (DSG2) protein were “strongly associated with significantly shorter survival in patients with multiple myeloma”.
The University said researchers analyzed clinical and genomic data from 678 recently diagnosed patients “and found that those with the highest levels of DSG2 faced substantially worse outcomes than patients with low levels of the protein”.
Adelaide University said the research, titled ‘Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile’ was published in the British Journal of Haematology at: https://doi.org/10.1111/bjh.70554.
The University said the study found “that patients with the highest DSG2 expression were linked to a significantly increased risk of both disease progression and death than those with the lowest expression levels”.
Adelaide University said the protein was “a strong predictor of patient outcomes even after accounting for age, disease stage, treatment type and stem cell transplantation”.
The University said the study showed “that DSG2 may help identify patients whose disease is more dangerous than current classifications suggest”.
Adelaide University said researchers believed further studies were needed “to validate the findings and investigate whether DSG2 itself could become a target for future therapies”.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has appointed Sydney's Healius Ltd as exclusive pathology distribution partner for its three Promarker blood tests in Australia.
Proteomics said it had a three-year partnership with Healius to distribute its tests including Promarker D for diabetic kidney disease, Promarker Eso for oesophageal cancer risk and Promarker Endo for endometriosis.
The company said the agreement provided it with access to Healius' more than 2,000 patient collection centres and established relationships with general practitioners, specialists, hospitals and other healthcare providers in Australia.
Proteomics said it would retain responsibility for the Promarker portfolio including laboratory testing, clinical reporting, scientific and medical support, quality and regulatory compliance.
The company said Healius would be responsible for pathology distribution through its national infrastructure, including specimen collection, referrer engagement, market access activities and support for its Promarker tests.
Proteomics said the agreement was "the first national commercial distribution partnership secured for the Promarker portfolio and establishes a national distribution pathway for commercial implementation across Australia".
The company said as the Promarker tests were "at an early stage of commercialization, the revenue that may be generated under the distribution agreement cannot be reliably estimated at this time".
Proteomics was up 3.5 cents or 23.3 percent to 18.5 cents with 2.2 million shares traded.

BLS PHARMACEUTICALS (BREATHE LIFE SCIENCES, FORMERLY BIOXYNE)

BLS says it has a non-binding agreement to commercialize the Brisbane-based Trexapharm's Trexavive neurotherapy for treatment-resistant depression in Australia.
BLS said that Trexavive was a non-sedating outpatient neurotherapy combining low doses of flumazenil and naltrexone for major depression disorder, with an open-label, 10-patient study showing symptom improvement at four-days post-administration.
According to the National Institutes of Health website, naltrexone was an opioid antagonist medication to treat alcohol use disorder and opioid use disorder while flumazenil was an injectable antidote used to reverse the sedative and respiratory-depressant effects of benzodiazepines.
The company said under the agreement it would become Trexapharm's preferred Australian commercial partner for Trexavive, using its relationships with psychiatrists, mental health clinics and healthcare providers to support the therapy's introduction into the Australian market.
BLS said it would support patient access through the Australian Therapeutic Goods Administration's special access scheme category B and authorized prescriber pathways, while also evaluating future manufacturing and supply opportunities.
The company said Trexapharm would retain responsibility for the clinical development of Trexavive and ownership of related intellectual property.
BLS said the parties intended "to explore opportunities into international markets, including the UK while also considering manufacturing and supply arrangements, veteran and defence menta health initiatives, broader commercial rights and partnerships and potential strategic investment opportunities.
The company did not disclose the commercial terms of the agreement.
BLS was up 1.5 cents or 1.8 percent to 85.5 cents.

PYC THERAPEUTICS

PYC says the safety review committee has approved the higher 2.4mg/kg dose in its phase Ib study of PYC-003 in patients with polycystic kidney disease.
Earlier this year, PYC said it dosed the first of up-to 48-patients in its phase Ib, open-label, multiple ascending dose study of PYC-003 for kidney disease (BD: May 7, 2026).
Today, the company said the approval followed review of the safety and tolerability data from the phase Ia single ascending dose study of PYC-003 at four weeks of follow-up after receiving a 2.4mg/kg dose and the three phase Ib patients dosed at a 1.2mg/kg dose.
PYC said the objective of the ongoing phase Ib multiple ascending dose study was to determine the safety and tolerability profile as well as optimal dosing regimen of PYC-003 in a repeat dose setting ahead of a proposed transition to a registrational trial.
The company said completion of the phase Ib study, alongside alignment with relevant regulatory authorities would lead to the opening of a registrational combined phase II/III trial aimed at supporting a new drug application for PYC-003 in kidney disease.
PYC said the results of its phase Ia single ascending dose study in polycystic kidney disease patients was expected to be presented this year, with phase Ib and open-label extension data expected to be presented in 2027.
PYC fell two cents or 1.2 percent to $1.605 with 1.6 million shares traded.

PARADIGM BIOPHARMACEUTICALS

Paradigm says it has received $5.75 million from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Paradigm said about $4,820,000 of the incentive related to expenditure for the year to June 30, 2025, with the remaining $930,000 following an amended income tax assessment for the year to June 30, 2023.
The company said the funds would be used for its phase III trial of injectable pentosan polysulfate sodium (PPS) for knee osteoarthritis, as well as regulatory activities.
Paradigm was up one cent or 6.1 percent to 17.5 cents with 3.2 million shares traded.

PAINCHEK

Painchek says it has received $1.123 million from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Painchek said the incentive related to research and development expenditure for the year to June 30, 2025, including development of its Adult and Infant pain management algorithms and validation activities supporting US commercialization.
Painchek was up half a cent or five percent to 10.5 cents.

MEMPHASYS

Memphasys says investors will vote to issue chair David Tasker 2,500,000 options and the Mr Tasker-related Chapter One Advisors 8,000,000 shares.
Memphasys said its extraordinary general meeting would vote to issue Chapter One Advisors the shares in lieu of cash for investor relations and consulting services, with Mr Tasker's options exercisable at 0.7 cents each by December 31, 2027.
The company said shareholders would vote to ratify the issue of placement shares and issue lead manager options.
The meeting will be held online on August 21, 2026 at 2pm (AEST).
Memphasys fell 0.1 cents or 12.5 percent to 0.7 cents.

VITURA HEALTH

Vitura says it has appointed James Frayne as its chief financial officer, effective from October 1, 2026, and Trudy Adams as head of strategy and technology.

Last month, Vitura said it had appointed former chief financial officer Tom Howitt as its interim chief financial officer, effective immediately, following the resignation of Andrew Cook "within the probationary period of his tenure" (BD: Jan 18; Jun 3, 5, 2026).

Today, the company said Mr Frayne was currently chief financial officer of ASX-listed "contractor management and procurement software" company Felix, as well as interim chief executive officer from November 2025 to April 2026.

Vitura said Mr Frayne held a Bachelor of Business and a Master of Business Administration from Brisbane's Queensland University of Technology.

The company said that Ms Adams had been chief operating officer at Vertaview Group and Health Insurance Fund (HIF) of Australia and had worked for Suncorp, Pricewaterhousecoopers (PWC), Coldwell Banker Richard Ellis (CBRE) and Bupa.

Vitura said Ms Adams was expected to begin the role on August 18, 2026.

According to her Linkedin profile, Ms Adams held a Bachelor of Laws and a Master of Business Administration from Brisbane's Queensland University of Technology.

The company said that Toni Cohen was the head of patient experience and growth; Josh Juhas the head of partnerships and distribution; Ruy Gustini the head of emerging markets and clinics; and Deanna Johns the head of people and culture.

Vitura was up 0.1 cents or 3.2 percent to 3.2 cents.